Long-Term Safety and Efficacy of Nevirapine-Based Approaches in HIV Type 1-Infected Patients
Anna Bonjoch(Universitat Autònoma de Barcelona), Bonaventura Clotet(IrsiCaixa), Jaume Mascaró(Hospital Universitari de Girona Doctor Josep Trueta), Enric Pedrol(Hospital General de Granollers), Josep M. Llibre(Hospital Sant Jaume de Calella), Àngels Masabeu(Hospital de Palamós), Jordi Puig(Universitat Autònoma de Barcelona), Lluís Force(University Hospital Mútua de Terrassa), Denise Cinquegrana(Johns Hopkins University), Peré Domingo(Hospital de Sant Pau), Núria Pérez‐Álvarez(Universitat Autònoma de Barcelona), Roger Paredes(Universitat Autònoma de Barcelona), Manel Cervantes, Josep Cucurull(Hospital de Figueres), David Dalmau(University Hospital Mútua de Terrassa), Josep Vilaró(Victoria General Hospital)
Cited by 42
Related Papers
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
Mpox in people with advanced HIV infection: a global case series
|The Lancet|2023|482
Gut Microbiota Linked to Sexual Preference and HIV Infection
|EBioMedicine|2016|480
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
|The Lancet Infectious Diseases|2011|172
Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2005|151